Oramed Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Oramed Pharmaceuticals is Nadav Kidron, benoemd in Mar2006, heeft een ambtstermijn van 18.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.66M, bestaande uit 27.9% salaris en 72.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.45% van de aandelen van het bedrijf, ter waarde $ 2.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 11.9 jaar en 8.2 jaar.

Belangrijke informatie

Nadav Kidron

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris	27.9%
Dienstverband CEO	18.7yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	11.9yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

Analyse CEO-vergoeding

Hoe is Nadav Kidron's beloning veranderd ten opzichte van Oramed Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$21m
Mar 31 2024	n/a	n/a	US$10m
Dec 31 2023	US$2m	US$463k	US$6m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$7m	US$491k	-US$37m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	n/a	n/a	-US$35m
Nov 30 2021	n/a	n/a	-US$25m
Aug 31 2021	US$4m	US$466k	-US$22m
May 31 2021	n/a	n/a	-US$18m
Feb 28 2021	n/a	n/a	-US$15m
Dec 31 2020	n/a	n/a	-US$22m
Nov 30 2020	n/a	n/a	-US$15m
Aug 31 2020	US$2m	US$439k	-US$12m
May 31 2020	n/a	n/a	-US$11m
Feb 29 2020	n/a	n/a	-US$13m
Nov 30 2019	n/a	n/a	-US$13m
Aug 31 2019	US$2m	US$419k	-US$14m
May 31 2019	n/a	n/a	-US$15m
Feb 28 2019	n/a	n/a	-US$15m
Nov 30 2018	n/a	n/a	-US$14m
Aug 31 2018	US$2m	US$436k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 1.66M ) Nadav } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van Nadav is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Nadav Kidron (50 yo)

18.7yrs

Tenure

US$1,659,222

Compensatie

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nadav Kidron	President	18.7yrs	US$1.66m	2.45% $ 2.3m
Miriam Kidron	Chief Scientific Officer & Director	18.7yrs	US$1.11m	0.21% $ 199.9k
Avraham Gabay	CFO, Treasurer & Secretary	less than a year	US$1.05m	geen gegevens
Joshua Hexter	Chief Operating & Business Officer	5.2yrs	US$1.28m	0.42% $ 401.0k

11.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ORMP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nadav Kidron	President	18.7yrs	US$1.66m	2.45% $ 2.3m
Miriam Kidron	Chief Scientific Officer & Director	18.7yrs	US$1.11m	0.21% $ 199.9k
Jay Skyler	Member of Scientific Advisory Board	4.8yrs	geen gegevens	geen gegevens
Eleuterio Ferrannini	Member of Scientific Advisory Board	17.8yrs	geen gegevens	geen gegevens
Harold Jacob	Member of Scientific Advisory Board	8yrs	US$20.00k	geen gegevens
Avram Hershko	Member of Scientific Advisory Board	16.3yrs	geen gegevens	geen gegevens
G. Alexander Fleming	Member of Scientific Advisory Board	4.9yrs	geen gegevens	geen gegevens
Leonard Sank	Independent Director	17.1yrs	US$112.28k	0.080% $ 75.5k
Roy Eldor	Member of the Scientific Advisory Board	8.3yrs	geen gegevens	geen gegevens
Anne Peters	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Arie Mayer	Independent Director	4.9yrs	US$127.28k	0.075% $ 71.1k
Julio Rosenstock	Member of Scientific Advisory Board	4.8yrs	geen gegevens	geen gegevens

8.2yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ORMP wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Oramed Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Recent updates

New minor risk - Market cap size

Investor sentiment improves as stock rises 21%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations